Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110630 · ClinicalTrials.gov registry record · Phase 3
Smoking Treatment of Prisoners
A Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT00110630 is a Phase 3 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 250 participants.
The verdict
NCT00110630, a Phase 3 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.
Interventions
- BEHAVIORAL 10-week smoking cessation group therapy combined with NicoDerm CQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110630
The ClinicalTrials.gov registry entry for NCT00110630 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 10-week smoking cessation group therapy combined with NicoDerm CQ is the first listed.
NCT00110630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110630 about?
NCT00110630 is a clinical study titled "Smoking Treatment of Prisoners". The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.
What is the current status of trial NCT00110630?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2005-06. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00110630?
The interventions under investigation include: 10-week smoking cessation group therapy combined with NicoDerm CQ (BEHAVIORAL).
Who is sponsoring clinical trial NCT00110630?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.